NASDAQ:AXNX Axonics (AXNX) Stock Price, News & Analysis → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free AXNX Stock Alerts $66.64 +0.17 (+0.26%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$66.50▼$66.8050-Day Range$66.47▼$69.6552-Week Range$47.59▼$69.68Volume396,114 shsAverage Volume1.27 million shsMarket Capitalization$3.40 billionP/E RatioN/ADividend YieldN/APrice Target$70.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Axonics alerts: Email Address Axonics MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside6.1% Upside$70.73 Price TargetShort InterestBearish6.75% of Shares Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews Sentiment1.82Based on 3 Articles This WeekInsider TradingSelling Shares$4.46 M Sold Last QuarterProj. Earnings Growth100.00%From $0.32 to $0.64 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.17 out of 5 starsMedical Sector328th out of 907 stocksSurgical & Medical Instruments Industry40th out of 96 stocks 1.2 Analyst's Opinion Consensus RatingAxonics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 5 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageAxonics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.75% of the outstanding shares of Axonics have been sold short.Short Interest Ratio / Days to CoverAxonics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Axonics has recently increased by 17.01%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAxonics does not currently pay a dividend.Dividend GrowthAxonics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxonics has received a 59.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Incontinence medication", "Implants and prostheses", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Axonics is -1.38. Previous Next 2.7 News and Social Media Coverage News SentimentAxonics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Axonics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for AXNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Axonics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axonics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,459,798.00 in company stock.Percentage Held by InsidersOnly 1.85% of the stock of Axonics is held by insiders.Percentage Held by Institutions99.48% of the stock of Axonics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Axonics are expected to grow by 100.00% in the coming year, from $0.32 to $0.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axonics is -512.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axonics is -512.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxonics has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Schaeffer’s ResearchJust Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.Yes! Show Me This Strategy About Axonics Stock (NASDAQ:AXNX)Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.Read More AXNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXNX Stock News HeadlinesApril 24, 2024 | prnewswire.comBoston Scientific Announces Results for First Quarter 2024April 4, 2024 | reuters.comFTC seeks more information on Boston Scientific's $3.7 bln Axonics dealApril 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.March 22, 2024 | businesswire.comAxonics Stockholders Approve Merger Agreement with Boston ScientificMarch 21, 2024 | businesswire.comAxonics Provides Update on Inter Partes Review ProceedingsMarch 14, 2024 | businesswire.comAxonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation SystemMarch 1, 2024 | finance.yahoo.comAxonics Full Year 2023 Earnings: EPS Beats ExpectationsFebruary 29, 2024 | marketwatch.comAxonics Pushes Back Against Patent Dispute Alleged by MedtronicApril 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.February 29, 2024 | businesswire.comAxonics Responds to ITC Action by MedtronicFebruary 29, 2024 | markets.businessinsider.comBeyond The Numbers: 7 Analysts Discuss Axonics StockFebruary 28, 2024 | finance.yahoo.comAxonics Inc (AXNX) Reports Robust Revenue Growth and Margin Expansion in Q4 and FY 2023February 27, 2024 | businesswire.comAXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNXFebruary 3, 2024 | finance.yahoo.comInsider Sell: Chief Medical Officer Karen Noblett Sells 11,288 Shares of Axonics Inc (AXNX)January 17, 2024 | finance.yahoo.comAre Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?January 16, 2024 | realmoney.thestreet.comAxonics just downgraded at Morgan Stanley, here's whyJanuary 16, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Axonics Modulation Technologies (AXNX) and Siemens Healthineers AG (OtherSEMHF)January 12, 2024 | realmoney.thestreet.comAxonics just downgraded at Truist, here's whyJanuary 12, 2024 | realmoney.thestreet.comAxonics just downgraded at CL King, here's whyJanuary 11, 2024 | realmoney.thestreet.comAxonics just downgraded at Leerink, here's whyJanuary 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Axonics Amid Strategic Acquisition by Boston ScientificJanuary 9, 2024 | msn.comBoston Scientific To Acquire Axonics For About $3.7 BlnJanuary 9, 2024 | msn.comUPDATE 3-Medical device maker Boston Scientific to buy Axonics for $3.7 billionJanuary 9, 2024 | markets.businessinsider.comAnalyst Scoreboard: 5 Ratings For AxonicsJanuary 8, 2024 | realmoney.thestreet.comAxonics just downgraded at RBC Capital, here's whyJanuary 8, 2024 | msn.comDrugmakers kick off industry conference with two cancer dealsJanuary 8, 2024 | investorplace.comWhy Is Axonics (AXNX) Stock Up 20% Today?See More Headlines Receive AXNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/25/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:AXNX CUSIPN/A CIK1603756 Webwww.axonics.com Phone(949) 396-6322Fax949-396-6321Employees797Year FoundedN/APrice Target and Rating Average Stock Price Target$70.73 High Stock Price Target$75.00 Low Stock Price Target$63.00 Potential Upside/Downside+6.1%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($0.13) Trailing P/E RatioN/A Forward P/E Ratio208.25 P/E GrowthN/ANet Income$-6,090,000.00 Net Margins-1.66% Pretax Margin-2.39% Return on Equity-1.00% Return on Assets-0.90% Debt Debt-to-Equity RatioN/A Current Ratio10.73 Quick Ratio8.98 Sales & Book Value Annual Sales$366.38 million Price / Sales9.28 Cash Flow$0.13 per share Price / Cash Flow529.18 Book Value$12.59 per share Price / Book5.29Miscellaneous Outstanding Shares51,000,000Free Float50,059,000Market Cap$3.40 billion OptionableOptionable Beta0.56 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Raymond W. Cohen (Age 65)CEO & Director Comp: $1.71MMr. Rinda K. Sama (Age 45)Chief Operating Officer Comp: $902.83kDr. John Woock Ph.D. (Age 41)Executive VP, Chief Marketing & Strategy Officer Comp: $902.83kMr. Alfred J. Ford Jr. (Age 53)Chief Commercial Officer Comp: $902.96kMs. Kari KeeseChief Financial OfficerMr. Guangqiang Jiang Ph.D. (Age 50)Chief Technology Officer Mr. Neil BhalodkarVice President of Investor RelationsMr. Aaron PettitGeneral Counsel & Chief Compliance OfficerMr. Michael V. Williamson Esq. (Age 52)J.D., Senior VP, General & IP Counsel Dr. Karen L. Noblett M.A.S. (Age 61)M.D., Chief Medical Officer Comp: $651.4kMore ExecutivesKey CompetitorsCantel MedicalNYSE:CMDiRhythm TechnologiesNASDAQ:IRTCPROCEPT BioRoboticsNASDAQ:PRCTHaemoneticsNYSE:HAEMerit Medical SystemsNASDAQ:MMSIView All CompetitorsInsiders & InstitutionsHedges Asset Management LLCSold 5,150 shares on 4/24/2024Ownership: 0.007%Allspring Global Investments Holdings LLCSold 503 shares on 4/18/2024Ownership: 0.096%Diversified Trust CoSold 5,325 shares on 4/18/2024Ownership: 0.015%Inspirion Wealth Advisors LLCBought 3,000 shares on 4/13/2024Ownership: 0.006%Fort Pitt Capital Group LLCBought 5,000 shares on 4/11/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions AXNX Stock Analysis - Frequently Asked Questions Should I buy or sell Axonics stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AXNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXNX, but not buy additional shares or sell existing shares. View AXNX analyst ratings or view top-rated stocks. What is Axonics' stock price target for 2024? 13 Wall Street research analysts have issued 12-month target prices for Axonics' stock. Their AXNX share price targets range from $63.00 to $75.00. On average, they expect the company's stock price to reach $70.73 in the next year. This suggests a possible upside of 6.1% from the stock's current price. View analysts price targets for AXNX or view top-rated stocks among Wall Street analysts. How have AXNX shares performed in 2024? Axonics' stock was trading at $62.23 on January 1st, 2024. Since then, AXNX shares have increased by 7.1% and is now trading at $66.64. View the best growth stocks for 2024 here. Are investors shorting Axonics? Axonics saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,440,000 shares, an increase of 17.0% from the March 15th total of 2,940,000 shares. Based on an average trading volume of 1,390,000 shares, the days-to-cover ratio is currently 2.5 days. View Axonics' Short Interest. When is Axonics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our AXNX earnings forecast. How were Axonics' earnings last quarter? Axonics, Inc. (NASDAQ:AXNX) announced its quarterly earnings results on Wednesday, February, 28th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.07. The firm had revenue of $109.70 million for the quarter, compared to the consensus estimate of $107.33 million. Axonics had a negative trailing twelve-month return on equity of 1.00% and a negative net margin of 1.66%. The firm's quarterly revenue was up 27.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.01 earnings per share. What ETFs hold Axonics' stock? ETFs with the largest weight of Axonics (NASDAQ:AXNX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), First Trust Merger Arbitrage ETF (MARB), AltShares Merger Arbitrage ETF (ARB), ProShares Merger ETF (MRGR), AltShares Event-Driven ET (EVNT), IQ Merger Arbitrage ETF (MNA), Fidelity Digital Health ETF (FDHT) and SPDR S&P Health Care Equipment ETF (XHE). What is Raymond W. Cohen's approval rating as Axonics' CEO? 20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend. What other stocks do shareholders of Axonics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT). When did Axonics IPO? Axonics (AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers. Who are Axonics' major shareholders? Axonics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.10%), Diversified Trust Co (0.01%), Fort Pitt Capital Group LLC (0.01%), Los Angeles Capital Management LLC (0.01%), Hedges Asset Management LLC (0.01%) and Inspirion Wealth Advisors LLC (0.01%). Insiders that own company stock include Alfred J Ford Jr, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Kari Leigh Keese, Raymond W Cohen, Raymond W Cohen and Rinda Sama. View institutional ownership trends. How do I buy shares of Axonics? Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AXNX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axonics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
